Glucose-lowering medications show differential longitudinal effects on glucagon and GLP-1 levels, with implications for understanding drug mechanisms and optimizing combination therapy.
Hormonal fingerprintsEach diabetes drug class creates a distinct pattern of glucagon/GLP-1 changes — understanding these patterns enables more precise drug selection
What the researchers found
Glucose-lowering medications show distinct longitudinal effects on glucagon and GLP-1 levels, informing drug mechanism understanding and combination optimization.
Why it matters
Understanding how each diabetes drug affects gut hormones helps predict effectiveness and design better combination therapies.
How the study worked
Longitudinal analysis of glucagon and GLP-1 levels during treatment with various glucose-lowering medications.
What this study cannot tell us
Details in full paper.
How to read the evidence
Longitudinal hormonal analysis.
When this study was published
Published in 2025.
The bigger picture
Hormonal profiling of diabetes drugs enables precision selection based on individual patients' hormonal patterns.
Questions still open
- Which drug combination provides optimal glucagon suppression + GLP-1 enhancement?
- Do hormonal effects predict clinical response?
- Should hormonal monitoring guide drug selection?
Common questions
Do diabetes drugs affect hormones differently?
Does this affect which drug I should take?
Read the original research
Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
Diabetes care, 49(2), 325-334
Citation
Kahn, Steven E; Tripputi, Mark; Lachin, John M; Balasubramanyam, Ashok; Banerji, Mary Ann; Barzilay, Joshua; Cohen, Robert M; Garvey, W Timothy; Gramzinski, Michaela R; Rasouli, Neda; Rhee, Mary; Seegmiller, Jesse C; Singh, Vatsala; Sivitz, William I; Steffes, Michael W; Utzschneider, Kristina; DeFronzo, Ralph A. (2026). Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).. Diabetes care, 49(2), 325-334. https://doi.org/10.2337/dc25-2186